Skip to Content

ConvaTec Group PLC ADR CNVVY

Morningstar Rating
$14.20 −0.14 (0.98%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Convatec Earnings: Investments in Innovation and Commercial Organization Set Up Strong 2024

Convatec finished the year with increasing strength, and we’ve increased our fair value estimate to $13.80 (GBX 271) per share. While green shoots since 2022 demonstrated mild progress as Convatec sought to engineer a turnaround, the last six months have been an inflection point, and we think the firm is firmly on the path to realizing its potential. While the rise in medical utilization likely boosted Convatec’s performance in 2023, the firm had also invested in its innovation and commercial organization and was prepared for these favorable conditions. We’ve long thought that Convatec had the ingredients to support a narrow moat, and the firm is getting closer to realizing that potential as it rides a wave of new product launches.

Price vs Fair Value

CNVVY is trading within a range we consider fairly valued.
Price
$14.20
Fair Value
$33.90
Uncertainty
Medium
1-Star Price
$63.73
5-Star Price
$5.13
Economic Moat
Lnfcbc
Capital Allocation
Wtfhwvrhj

Bulls Say, Bears Say

Bulls

Convatec's well-established footprint in the U.S. ostomy market has paved the way to forge contracts with large group purchasing organizations, including Premier and Vizient.

Bears

Considering that ostomy patients tend to be brand loyal after the first year postdischarge, we expect Convatec's ostomy business to grow gradually as it takes greater share of new patient discharges.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CNVVY is a good fit for your portfolio.

Trading Information

Previous Close Price
$14.34
Day Range
$14.2014.20
52-Week Range
$9.9015.40
Bid/Ask
$13.71 / $14.63
Market Cap
$7.28 Bil
Volume/Avg
161 / 5,626

Key Statistics

Price/Earnings (Normalized)
24.38
Price/Sales
3.38
Dividend Yield (Trailing)
1.75%
Dividend Yield (Forward)
1.75%
Total Yield
1.75%

Company Profile

Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Growth
Total Number of Employees
10,136

Competitors

Valuation

Metric
CNVVY
SNN
BDX
Price/Earnings (Normalized)
24.3813.5520.22
Price/Book Value
4.272.072.75
Price/Sales
3.381.943.58
Price/Cash Flow
19.3711.4521.44
Price/Earnings
CNVVY
SNN
BDX

Financial Strength

Metric
CNVVY
SNN
BDX
Quick Ratio
0.790.670.46
Current Ratio
1.621.771.08
Interest Coverage
3.212.844.17
Quick Ratio
CNVVY
SNN
BDX

Profitability

Metric
CNVVY
SNN
BDX
Return on Assets (Normalized)
7.44%7.27%3.40%
Return on Equity (Normalized)
16.69%13.79%7.05%
Return on Invested Capital (Normalized)
10.90%9.92%5.04%
Return on Assets
CNVVY
SNN
BDX
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncGfkbzysvJcs$136.4 Bil
BDX
Becton Dickinson & CoKggbplbbzBnztzrp$67.9 Bil
ALC
Alcon IncKbdkwjwxLzjrngx$40.2 Bil
CLPBY
Coloplast A/S ADRQsnyrrcdwFqwqc$29.9 Bil
WST
West Pharmaceutical Services IncLfmlfyrhXxlk$28.5 Bil
RMD
ResMed IncJntrftmgtFrdlpnn$27.3 Bil
BAX
Baxter International IncZzppztcxBsjbnxs$20.5 Bil
COO
The Cooper Companies IncLwrnnrrwPylcm$18.6 Bil
HOLX
Hologic IncMhfcshdfDxxfqm$18.2 Bil
TFX
Teleflex IncKyhcRdfz$10.1 Bil

Sponsor Center